# Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

Study · id `cardio:ct-nct03658031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03658031](<https://clinicaltrials.gov/study/NCT03658031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03658031

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 576 participants.

## Technical summary

Registry record NCT03658031. Randomized; no masking; primary purpose treatment. Start 2019-03-01 (anticipated); primary completion 2020-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 576 participants (planned count; ClinicalTrials.gov record NCT03658031, source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)
- Planned start: 2019-03-01 (anticipated) (ClinicalTrials.gov record NCT03658031, source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)
- Primary completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03658031, source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)
- Completion: 2021-01-31 (anticipated) (ClinicalTrials.gov record NCT03658031, source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)
- Countries: Qatar (ClinicalTrials.gov record NCT03658031, source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03658031-2019-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
- Condition: PreDiabetes
- Condition: Myocardial Infarction
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Condition: CVD
- Intervention (Drug): Dapagliflozin 10mg
- Lead sponsor: Hamad Medical Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Hamad Medical Corporation (`cardio:org-hamad-medical-corporation`)

## Provenance

Content hash: 6515e5ed8e4c3624bca0a908962785b5c172b3e2df8c43fcd007c6375d2f4a85
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
